Reported today during a Proffered Paper session at the ESMO Gastrointestinal Cancers Annual Congress (ESMO GI) 2024*, first health-related quality of life (HRQoL) results of the Checkmate 8HW study—the first phase III trial to evaluate first-line nivolumab plus ipilimumab in patients with unresectable microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer—show that this combination immunotherapy decreased the risk of HRQoL deterioration and reduced symptoms versus standard chemotherapy.
Presented by first author Sara Lonardi, Chief of the Gastrointestinal Cancers Unit at the Veneto Institute of Oncology (IVO – IRCCS) in Padua, and co-authored by VHIO’s Elena Élez, these data build on initial results from this international, multicenter, open-label, randomized study that were presented last January at the 2024 ASCO Gastrointestinal Cancers Symposium.
The investigators previously reported that this dual immunotherapy regimen reduced the risk of disease progression by 79% compared with chemotherapy, and that half of the patients who received the dual immunotherapy remained free of disease progression at 24.3 months vs. 5.8 months in patients who were treated with chemotherapy.
Assessment and reporting of quality-of-life measures
“In addition to the appropriate selection of clinical endpoints such as response rate and progression-free survival, assessing health-related quality of life Élez, Medical Oncologist at the Vall d’Hebron University Hospital and Group Leader of VHIO’s Colorectal Cancer Group.
The investigators analyzed symptoms and various factors affecting the quality of life of patients included in this study. At a median of 31.5 months follow-up, they observed improved HRQoL, reduced symptoms, and a decreased risk of health deterioration in patients who received the combination of nivolumab plus ipilimumab compared with those who were treated with standard chemotherapy.
“The next step will be to evaluate the efficacy of this combination versus a PD-1 inhibitor alone given that this is the current standard of care for this patient population,” concludes Élez.
###
Reference
*ESMO Gastrointestinal Cancers Annual Congress 2024, 26 – 29 June, Munich, Germany
Session Details:
Proffered Paper session
Date: Thursday, 27 June
Session Time: 14:00h – 15:35h (CEST)
Chairs: Teresa Macarulla (Barcelona Spain), Eric Van Cutsem (Leuven, Belgium)
Abstract:
2O – Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC).
Sara Lonardi (Padova, Italy), Thierry André (Paris, France), Dirk Arnold (Hamburg, Germany), Rocio Garcia-Carbonero (Madrid, Spain), Myriam Chalabi (Amsterdam, Netherlands), Maria Elena Elez Fernandez (Barcelona, Spain), Heinz Josef Lenz (Los Angeles, United States of America), Lars Henrik Jensen (Vejle, Denmark), Rohit Joshi (Adelaide, Australia), Jeanine M. Roodhart (Utrecht, Netherlands), Takayuki Yoshino (Kashiwa, Japan), Matthew Dixon (Princeton, United States of America), Steven I. Blum (Princeton, United States of America), Joel Sims (Cheshire, United Kingdom), Rachael Lawrance (Cheshire, United Kingdom), Fiona Taylor (Boston, United States of America), Tian Chen (Princeton, United States of America), Elvis Cela (Princeton, United States of America), Lixian Jin (Princeton, United States of America), Eric Van Cutsem (Leuven, Belgium).
Lecture Time: 14:10h – 14:20h
Speaker: Sara Lonardi (Padua, Italy)
